Wang S, Guan YG, Zhu YH, Wang MZ. Role of high mobility group box protein 1 in depression: A mechanistic and therapeutic perspective. World J Psychiatry 2022; 12(6): 779-786 [PMID: 35978968 DOI: 10.5498/wjp.v12.i6.779]
Corresponding Author of This Article
Min-Zhong Wang, MBBS, MD, PhD, Associate Professor, Deputy Director, Department of Neurology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, No. 324 Jingwuweiqi Road, Jinan 250021, Shandong Province, China. wmzwlq@163.com
Research Domain of This Article
Neurosciences
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Psychiatry. Jun 19, 2022; 12(6): 779-786 Published online Jun 19, 2022. doi: 10.5498/wjp.v12.i6.779
Role of high mobility group box protein 1 in depression: A mechanistic and therapeutic perspective
Shu Wang, Yu-Guang Guan, Yan-Hua Zhu, Min-Zhong Wang
Shu Wang, Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China
Yu-Guang Guan, Department of Neurosurgery, Sanbo Brain Hospital, Capital Medical University, Beijing 100093, China
Yu-Guang Guan, Beijing Key Laboratory of Epilepsy, Center of Epilepsy, Beijing Institute of Brain Disorders, Collaborative Innovation Center for Brain Disorders, Capital Medical University, Beijing 100093, China
Yan-Hua Zhu, Department of Cardiology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, Shandong Province, China
Min-Zhong Wang, Department of Neurology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, Shandong Province, China
Author contributions: Wang S performed the majority of the writing; Guan YG coordinated the writing of the paper; Zhu YH and Wang MZ designed the outline and coordinated the writing of the paper; Zhu YH and Wang MZ contributed equally to this work as co-corresponding authors.
Conflict-of-interest statement: The authors declare that they have no conflicts of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Min-Zhong Wang, MBBS, MD, PhD, Associate Professor, Deputy Director, Department of Neurology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, No. 324 Jingwuweiqi Road, Jinan 250021, Shandong Province, China. wmzwlq@163.com
Received: January 6, 2022 Peer-review started: January 6, 2022 First decision: March 13, 2022 Revised: April 12, 2022 Accepted: May 14, 2022 Article in press: May 14, 2022 Published online: June 19, 2022 Processing time: 158 Days and 23.7 Hours
Abstract
As a common and serious psychiatric disorder, depression significantly affects psychosocial functioning and quality of life. However, the mechanism of depression is still enigmatic and perplexing, which limits its precise and effective therapeutic methods. Recent studies demonstrated that neuroinflammation activation plays an important role in the pathophysiology of depression. In this respect, high mobility group box 1 (HMGB1) may be a possible signaling inducer of neuroinflammation and can be a potential mechanistic and therapeutic target for depression. Herein, we review recent studies on the mechanistic and therapeutic targets of HMGB1 in depression and propose potential perspectives on this topic.
Core Tip: Limited reviews in the literature contributed to the high mobility group box 1 (HMGB1) in depression. This review provides a comprehensive mechanistic and therapeutic perspective on this topic and proposed that the future perspectives of HMGB1 in depression should be understanding the full signaling pathway of HMGB1 in depression, deeply investigating potential HMGB1 related therapeutic targets, and exploring the role of HMGB1 in depression and combined disease.
